Presentation for Investors

FY2011 (April 1 – March 31, 2012) Financial Results

Translation of presentation material for the investor meeting held in Tokyo on May 15, 2012

(¥billion)

FY2011 PL ₍₁₎	F	FY2010		F	FY2011		C	Chang	е			FY2011 Outloo		
	1H	2H	Total	1H	2H	Total	1H	2H	Total	1H	2H(A) as of Oct.2011	2H(B) as of Mar.2012	as of	Total(B) as of Mar.2012
Sales	72.1	82.1	154.2	69.8	78.8	148.6	-2.3	-3.3	-5.6	69.8	86.2	78.2	156.0	148.0
Operating Profit	8.3	11.5	19.8	6.6	8.9	15.5	-1.7	-2.6	-4.3	6.6	11.9	8.4	18.5	15.0
Non-Operating Income/Expenses	-0.5	0.1	-0.4	-0.1	0.5	0.4	0.4	0.4	0.8	-0.1	0.1	0.1	0.0	0.0
Ordinary Income	7.8	11.6	19.4	6.5	9.4	15.9	-1.3	-2.2	-3.5	6.5	12.0	8.5	18.5	15.0
Extraordinary Profit/Loss	-	-0.5	-0.5	-	0.7	0.7	-	1.2	1.2	-	0.2		0.2	
Net Income	5.6	7.4	13.0	4.4	6.6	11.0	-1.2	-0.8	-2.0	4.4	8.3	5.9	12.7	10.3
EBITDA (2)	13.2	17.0	30.2	11.5	14.4	25.9	-1.7	-2.6	-4.3	11.5	17.7		29.2	
EPS (¥)	32.81	43.13	75.94	25.88	38.64	64.52	-6.93	-4.49	-11.42	25.88	48.78	34.67	74.66	60.55
Dividend (¥/share)	¥12	¥12	¥24	¥12	¥12	¥24	¥0	¥0	¥0	¥12	¥12		¥24	
Total amount of Dividend	2.1	2.0	4.1	2.1	2.0	4.1	0	0	0	2.1	2.0		4.1	
OP Margin(%)	11.6%	14.0%	12.9%	9.4%	11.3%	10.4%	-2.2%	-2.7%	-2.5%	9.4%	13.7%	10.7%	11.9%	10.1%
ROE(%)			11.9%			9.5%			-2.4%					
FX Rate (¥/\$)	89	82		80	82					80	80			
Naphtha(¥/KL)	46,900	48,500		57,000	52,800					57,000	54,000			
		$\overline{}$		$\overline{}$			1							

11.5

12.1

Comprehensive Income

⁽¹⁾ FY2011 = April 1, 2011 ~March 31, 2012

⁽²⁾ EBITDA = Operating Profit + Depreciation

2H FY2011 Review

```
<vs. 2H FY2010>
           (Sales) ◆Down ¥3.3 billion (±) Pharmaceuticals
                                       (-) Chemicals, Performance Materials, Agrochemicals, Trading
             (OP) ◆Down ¥2.6 billion (-) Chemicals, Performance Materials, Agrochemicals,
                                          Pharmaceuticals, Trading
 (Ordinary Income) ◆Down ¥2.2 billion
     (Net Income) ◆Down ¥0.8 billion
<vs. 2H FY2011 Outlook as of October 2011>
           (Sales) ◆Down ¥7.4 billion (+) Pharmaceuticals
                                       (-) Chemicals, Performance Materials, Agrochemicals, Trading
             (OP) Down ¥3.0 billion (+) Agrochemicals, Pharmaceuticals
                                       (-) Chemicals, Performance Materials, Trading
 (Ordinary Income) ◆Down ¥2.6 billion
     (Net Income) ◆Down ¥1.7 billion
< Dividend >
```

◆¥12 Same as 2H FY2011 Outlook as of October 2011

2H FY2011 Review

FY2011 Review

```
<vs. FY2010>
             (Sales) Down ¥5.6 billion(-3.6%) (+) Pharmaceuticals, Trading
                                                  (-) Chemicals, Performance Materials, Agrochemicals
                (OP) Down ¥4.3 billion(-21.9%) (+) Pharmaceuticals
                                                  (-) Chemicals, Performance Materials, Agrochemicals, Trading
         (OP Margin) ◆10.4% More than 10% OP Margin in 9 consecutive years
      (Non-Operating ◆Up ¥0.8 billion
                                                 Foreign exchange losses +0.6
Income and Expenses)
                                                  Equity in earnings of affiliates +0.6. Others -0.4
  (Ordinary Income) ◆Down ¥3.5 billion(-18.1%)
        (Net Income) ◆Down ¥2.0 billion (-15.2%)
              (ROE) ◆9.5%
   <Dividend>
          (Dividend) $\div \text{\frac{\pmatrix}{24/share}}$ Dividend payout ratio 37.2%
```

FY2011

Non-Operating Income/Expenses, Extraordinary Profit/Loss,

Comprehensive Income (¥billion)

	FY2010	FY2011	Change
Non-Operating Income	2.03	2.28	0.25
Interest income	0.04	0.03	-0.01
Dividend income	0.55	0.56	0.01
Others	1.44	1.69	0.25
Non-Operating Expenses	2.48	1.89	-0.59
Interest expense	0.50	0.45	-0.05
Loss on disposal of fixed assets	0.45	0.24	-0.21
Others	1.53	1.20	-0.33
Extraordinary Profit (1)	0.11	0.65	0.54
Extraordinary Loss (2)	-0.63	0.00	0.63
Comprehensive Income	12.05	11.48	-0.57
Net income	12.95	10.98	-1.97
Minority interests	0.07	80.0	0.01
Unrealized gains or losses on investment securities	-0.45	0.58	1.03
Foreign currencytranslation adjustments	-0.52	-0.16	0.36

⁽¹⁾ FY2010: Reversal of provision for loss on business liquidation 0.11

FY2011: Gain on sales of business 0.65

(2) FY2010: One-time losses caused by a change in employees' retirement benefit plan -0.63

FY2011 Cash Flows

(¥billion)

	FY2010			F	Y201	1	Change			FY2011 Outlook as of October 2011		
	1H	2H	Total	1H	2H	Total	1H	2H	Total	1H	2H	Total
CF from operating activities	21.8	2.9	24.7	20.4	0.9	21.3	-1.4	-2.0	-3.4	20.4	-1.4	19.0
Profit before income tax	7.8	11.1	18.9	6.5	10.0	16.5	-1.3	-1.1	-2.4	6.5	12.2	18.7
Depreciation & Amortization	4.9	5.5	10.4	4.9	5.6	10.5	0.0	0.1	0.1	4.9	5.8	10.7
Tax	-3.7	-2.8	-6.5	-3.1	-2.9	-6.0	0.6	-0.1	0.5	-3.1	-3.0	-6.1
Working capital, others	12.8	-10.9	1.9	12.1	-11.8	0.3	-0.7	-0.9	-1.6	12.1	-16.4	-4.3
CF from investing activities	-2.9	-5.4	-8.3	-6.3	-3.0	-9.3	-3.4	2.4	-1.0	-6.3	-6.3	-12.6
Purchase of investments in securities	0.6	0.0	0.6	-0.9	0.1	-0.8	-1.5	0.1	-1.4	-0.9	0.0	-0.9
Purchase of PPE	-2.7	-5.8	-8.5	-4.9	-3.8	-8.7	-2.2	2.0	-0.2	-4.9	-6.3	-11.2
Others	-0.8	0.4	-0.4	-0.5	0.7	0.2	0.3	0.3	0.6	-0.5	0.0	-0.5
CF from financing activities	-18.3	8.7	-9.6	-9.6	4.5	-5.1	8.7	-4.2	4.5	-9.6	3.6	-6.0
Dividends paid	-2.4	-2.1	-4.5	-2.0	-2.1	-4.1	0.4	0.0	0.4	-2.0	-2.0	-4.0
Borrowings	-13.0	10.8	-2.2	-7.5	6.5	-1.0	5.5	-4.3	1.2	-7.5	5.6	-1.9
Purchase of treasury shares	-2.8	0.0	-2.8	0.0	0.0	0.0	2.8	0.0	2.8	0.0	0.0	0.0
Others	-0.1	0.0	-0.1	-0.1	0.1	0.0	0.0	0.1	0.1	-0.1	0.0	-0.1
Effect of FX rate changes on cash & cash equivalents	-0.3	-0.2	-0.5	-0.4	0.3	-0.1	-0.1	0.5	0.4	-0.4	0.0	-0.4
Change in cash & cash equivalents	0.3	6.0	6.3	4.1	2.7	6.8	3.8	-3.3	0.5	4.1	-4.1	0.0
Cash & cash equivalents at end of period	15.1	21.1	_	25.2	27.9	_	10.1	6.8		25.2	21.1	

FY2011 Balance Sheets

(¥billion)

	2011/3	2012/3	Change
Current assets	110.5	118.4	7.9
Cash	21.1	27.9	6.8
Accounts receivable	55.2	55.5	0.3
Inventories	28.4	29.4	1.0
Others	5.8	5.6	-0.2
Fixed assets	72.9	71.7	-1.2
Total PPE	46.4	44.7	-1.7
Intangible assets	3.4	2.8	-0.6
Investment securities	20.3	22.3	2.0
Others	2.8	1.9	-0.9
Total assets	183.4	190.1	6.7

	2011/3	2012/3	Change
Liabilities	71.0	70.5	-0.5
Accounts payable	15.4	17.3	1.9
Borrowings	39.9	38.9	-1.0
Others	15.7	14.3	-1.4
Net assets	112.4	119.6	7.2
Shareholders' equity	111.1	118.0	6.9
Unrealized gains or losses on investment securities	1.4	2.0	0.6
Foreign currencytranslation adjustments	-1.2	-1.4	-0.2
Minority interests	1.1	1.0	-0.1
Total liabilities & Net assets	183.4	190.1	6.7
(D/E Ratio)(1)	16.9% 60.7%	9.3%	

(Equity Ratio) 60.7% 62.4%

(Blank)

New Segmentation (From 2Q 2011)

- ◆Reflecting organizational changes implemented in June 2011
- Major organizational change

Creation of Performance Materials Division to consolidate Electronic Materials Division and Inorganic Materials Division aiming to strengthen performance materials business which is identified as our major growth engine

- Major changes in segmentation

 - Creation of Performance Materials → Electronic Materials + Inorganic Materials
 - **Change in Chemicals**

→ Inorganic Materials shifted to Performance Materials Creation of Fine Chemicals subsegment, abolishment of Organic Materials subsegment **Environmental Chemicals (HI-LITE) shifted from basic Chemicals to Fine Chemicals**

Adjustment

	Former Segi	mentation					
Segment	M	ain Products					
Chem	Organic Materials	TEPIC Melamine cyanurate Custom Chemicals					
	Inorganic Materials	SNOWTEX Organo sillica sol Alumina sol SUNCOLLOID CELNAX					
	Basic Chemicals	Melamine Urea, AdBlue HI-LITE Ammonia, Sulfuric acid, Nitric acid High purity chemicals					
Electronic Materials	SUNEVER, BARC NHC Multi layer process ma Micro lens	aterials					
Agro Chem	Agro	Herbicides Insecticides Fungicide					
Pharma	LIVALO]					
Trading	Nissei Corporation						
Others	Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, Fertilizer						
Adjustment	R&D expenses of Advance	d Materials & Planning Dept. included					

	New Segme	entation					
Segment	Ma	ain Products					
Chem	Fine	TEPIC					
	Chemicals	Melamine cyanurate					
	HI-LITE						
	Custom Chemicals						
	Basic	Melamine					
	Chemicals	Urea, AdBlue					
		Ammonia, Sulfuric acid, Nitric acid					
	High purity chemicals						
Performance	SUNEVER, BARC, NHC,						
Materials	Multi layer process ma	terials					
	Micro lens						
	SNOWTEX, Organo sil	lica sol					
	Alumina sol, SUNCOLI	LOID					
	CELNAX						
Agro Chem	Agro	Herbicides					
		Insecticides					
		Fungicide					
Pharma	LIVALO						
Trading	Nissei Corporation						
Others	Nissan Butsuryu, Niss	an Green & Landscape,					
	Nissan Engineering, F	ertilizer					

R&D expenses of Advanced Materials & Planning Dept. included

Diversified Product Portfolio

♦ Consisting of products holding strong position in market

	(¥ billion)			NCI's Position
Chem	FY2011 Sales	TEPIC	Epoxy compound for painting, LED sealant, solder resist	Largest (World)
Fine Chemicals	11.0 (7.4%)	High purity sulfuric acid	Agents for cleaning semiconductors	Largest (Japan)
Basic	25.9	AdBlue	Urea to reduce NOx for diesel trucks	Among top 3 (Japan)
Chemicals	(17.4%)			
Performance	34.0	SUNEVER	LCD alignment coating	Major (Asia)
Materials	(22.9%)	BARC	Bottom-anti-reflective coating for semiconductor	Largest (Asia)
Agro	33.8	SNOWTEX	Silica sol for polishing silicon wafer	Largest (Japan)
7.5.0	(22.7%)		catalyst, non-chrome electrical steel sheet, etc.	
Pharma	10.0 (6.8%)	ROUNDUP	Non-selective herbicide	Largest (Japan)
	44.8	SIRIUS	Paddy rice herbicide	No.3 (Japan)
Trading	(30.2%)			
	20.0	LIVALO	Anti-cholesterol drug	No.3 (Japan)
Others	(13.4%)			12

FY2011 Sales by Segment₍₁₎

(¥billion)

	FY2010			ı	FY2011		Change		
	1H	2H	Total	1H	2H	Total	1H	2H	Total
Chem	18.5	19.6	38.1	18.6	18.3	36.9	0.1	-1.3	-1.2
Fine Chemicals	6.1	5.2	11.3	5.9	5.0	10.9	-0.2	-0.2	-0.4
Basic Chemicals	12.4	14.4	26.8	12.7	13.3	26.0	0.3	-1.1	-0.8
Performance Materials	19.7	18.3	38.0	17.0	17.0	34.0	-2.7	-1.3	-4.0
Agro	12.0	22.4	34.4	12.5	21.3	33.8	0.5	-1.1	-0.6
Pharma	4.8	4.8	9.6	5.2	4.8	10.0	0.4	0.0	0.4
Trading	21.2	22.9	44.1	22.5	22.3	44.8	1.3	-0.6	0.7
Others	11.1	15.9	27.0	9.3	10.7	20.0	-1.8	-5.2	-7.0
Adjustment	-15.2	-21.8	-37.0	-15.3	-15.6	-30.9	-0.1	6.2	6.1
Total	72.1	82.1	154.2	69.8	78.8	148.6	-2.3	-3.3	-5.6

(+51111011)									
FY2011 Outlook as of October 2011									
1H	2H E	Total							
18.6	20.7	39.3							
5.9	5.9	11.8							
12.7	14.8	27.5							
17.0	20.3	37.3							
12.5	22.2	34.7							
5.2	4.6	9.8							
22.5	25.8	48.3							
9.3	11.1	20.4							
-15.3	-18.5	-33.8							
69.8	86.2	156.0							

⁽¹⁾ FY2010 are restated based on new segmentation

FY2011 OP by Segment (1)

(¥billion)

	FY2010			I	FY2011		Change		
	1H	2H	Total	1H	2H	Total	1H	2H	Total
Chem	0.6	1.8	2.4	8.0	8.0	1.6	0.2	-1.0	-0.8
Fine Chemicals	-	-	-	-	-	-	-	-	-
Basic Chemicals	-	1	1	-	1	1	1	1	1
Performance Materials	4.9	3.0	7.9	2.6	2.2	4.8	-2.3	-0.8	-3.1
Agro	0.8	4.0	4.8	8.0	3.6	4.4	0.0	-0.4	-0.4
Pharma	2.1	2.3	4.4	2.6	2.0	4.6	0.5	-0.3	0.2
Trading	0.7	0.7	1.4	0.7	0.6	1.3	0.0	-0.1	-0.1
Others	0.1	0.9	1.0	0.0	0.3	0.3	-0.1	-0.6	-0.7
Adjustment	-0.9	-1.2	-2.1	-0.9	-0.6	-1.5	0.0	0.6	0.6
Total	8.3	11.5	19.8	6.6	8.9	15.5	-1.7	-2.6	-4.3

	(+	Dillion									
	FY2011 Outlook as of October 2011										
1H	2HE	Total									
8.0	2.1	2.9									
•	1	1									
-	-	-									
2.6	4.3	6.9									
8.0	3.4	4.2									
2.6	1.7	4.3									
0.7	0.9	1.6									
0.0	0.3	0.3									
-0.9	-0.8	-1.7									
6.6	11.9	18.5									

⁽¹⁾ FY2010 are restated based on new segmentation

2H FY2011 Review by Segment

(Chemicals) (vs.2H FY2010)

(Basic Chemicals) ◆OP down

◆Naphtha cost increase as well as sales decrease in melamine

◆Urea/AdBlue sales up, fixed cost down

(Fine Chemicals) ◆OP flat

♦ Sales down (Custom Chemicals up, but other products down due to strong yen and weak electronic appliances market)

15

Fixed cost down

(Total Segment) Sales down ¥1.3billion. OP down ¥1.0billion

(vs.2H FY2011 Outlook as of October 2011)

(Basic Chemicals) Demand for melamine and major products below outlook

(Fine Chemicals) • Except Custom Chemicals, sales below expectations due to strong ven and weak electronic appliances market)

(Total Segment) Sales down ¥2.4billion. OP down ¥1.3billion

(Performance Materials)

(vs.2H FY2010)

◆Sales down ¥1.3billion, OP down ¥0.8billion

◆Sales decrease in TN, VA, BARC(including non-BARC ArF), SNOWTEX

◆Substantial sales increase in IPS/FFS, 3D TV materials launched

Fixed cost up

(vs.2H FY2011 Outlook as of October 2011)

◆Sales down ¥3.3billion, OP down ¥2.1billion

Except VA, all major products sales below expectations due to weak respective market conditions

(Agro)

(vs.2H FY2010)

♦ Sales down ¥1.1billion, OP down ¥0.4billion

Paddy rice herbicide down, some licensed-in contracts discontinued

◆Marketing cost up, depreciation cost up (new Biological Research Laboratories), R&D expenses up

(vs.2H FY2011 Outlook as of October 2011)

◆Sales down ¥0.9billion, OP up ¥0.2billion

◆Sales of some paddy rice herbicide and licensed-in products below outlook

♦Cost cut, shift to higher margin products

(Pharmaceuticals)

(vs.2H FY2010)

◆Sales flat, OP down ¥0.3billion

◆LIVALO sales up ¥0.4billion, milestones down ¥0.5billion

Depreciation cost up (new Biological Research Laboratories)

(vs.2H FY2011 Outlook as of October 2011)

◆Sales up ¥0.2billion, OP up ¥0.3billion

♦ Domestic LIVALO sales above expectations, fixed cost below outlook

(Trading)

(vs.2H FY2010 and vs.2H FY2011 Outlook as of October 2011)

♦ Sales and OP down due to smaller trading activities

FY2011 YOY Review by Segment

(Chemicals)

(Basic Chemicals) ◆OP down

◆Slight OP decrease in 1H, large OP decrease in 2H due to sales decrease in melamine though urea/ AdBlue sales up, and fixed cost down

(Fine Chemicals) ◆OP up

◆Custom Chemicals sales up, other products sales down

♦Fixed cost down

(Total Segment) ◆Sales down ¥1.2billion, OP down ¥0.8billion

(Performance Materials)

- ◆Sales down ¥4.0billion, OP down ¥3.1billion
- ◆Sales decrease in TN, VA, BARC(including non-BARC ArF), SNOWTEX
- ◆Substantial sales increase in IPS/FFS, BARC ArF volume up, new products sales up 36%
- **♦** Fixed cost up (new SNOWTEX plant completed in March 2011)

(Agro)

- ◆Sales down ¥0.6billion, OP down ¥0.4billion
- ◆Though in-house developed products sales up (ROUNDUP, LEIMAY, STARMITE, THIFLUZAMIDE, etc.), no milestones on the animal health products received as expected

(Pharmaceuticals)

- ◆Sales up ¥0.4billion (LIVALO up ¥0.7billion, milestones down ¥0.2billion), OP up ¥0.2billion
- ◆Depreciation cost up (new plant, new Biological Research Laboratories), cost cut

(Trading)

- ◆Sales up ¥0.7billion, OP down ¥0.1billion
- Recovery in 1H, lower trading activities in 2H

FY2011 Outlook (¥billion) FY2011 FY2012F Change Total 1HE 1HE 2H E Total **1H 2H** 2HE Total Sales 148.6 69.8 78.8 69.4 83.6 153.0 -0.4 4.8 4.4 **Operating Profit** 6.6 8.9 15.5 6.3 10.9 17.2 -0.3 2.0 1.7 -0.1 0.5 0.4 -0.2 0.4 0.2 -0.1 -0.1 -0.2 Non-Operating Income/Expenses 6.5 9.4 15.9 6.1 11.3 17.4 -0.4 1.9 1.5 Ordinary Income 0.7 0.7 -0.7 Extraordinary Profit/Loss -0.7 6.6 3.6 Net Income 4.4 11.0 7.8 11.4 -0.8 1.2 0.4 EBITDA (1) 11.5 14.4 25.9 10.8 16.4 27.2 -0.7 2.0 1.3 **EPS (¥) (2)** 25.88 38.64 64.52 20.93 46.26 67.19 -4.95 7.62 2.67 Dividend (¥/share) ¥12 ¥12 ¥24 ¥12 ¥12 ¥24 ¥0 ¥0 ¥0 1.9 3.9 Total amount of Dividend (2) 2.1 2.0 4.1 2.0 -0.1 -0.1 -0.2 OP Margin(%) 11.3% 10.4% 11.2% 9.4% 9.1% 13.0% -0.3% 1.7% 0.8% **ROE(%) (2)** 9.5% 9.5% 0.0% FX Rate (¥/\$) 80 82 77 **77**

Comprehensive income 12.1

Naphtha(¥/kl)

57,000 | 52.800

53,000 | 53,000

⁽¹⁾ EBITDA = Operating Profit +Depreciation

⁽²⁾ EPS, Total amount of Dividend, ROE based on purchase of treasury shares announced on May 15, 2012

FY2012 Outlook

```
< vs FY2011>
            (Sales) \downarrow Up ¥4.4 billion (+2.9%) (+) Chemicals, Performance Materials,
                                                   Agrochemicals, Trading
                                                (-) Pharmaceuticals
                    ◆ Up ¥1.7 billion (+10.9%) (+) Chemicals, Performance Materials, Trading
                                                (-) Agrochemicals, Pharmaceuticals
     (Non-Operating
                     ♦ Down ¥0.2 billion
                                                Foreign exchange losses +0.1
Income and Expenses)
                                                Equity in earnings of affiliates -0.1
                                                 Others -0.2
 (Ordinary Income) ♦ Up ¥1.5 billion (+9.4%)
      (Net Income) ◆ Up ¥0.4 billion(+3.6%) Extraordinary Profit/Loss -0.7
    < Dividend > ◆¥12 both 1H and 2H, same as FY2011
```

FY2012 Cash Flows Outlook

(¥billion)

	2011	2012E
CF from operating activities	21.3	22.4
Profit before income tax	16.5	17.4
Depreciation & Amortization	10.5	10.0
Tax	-6.0	-4.8
Working capital, others	0.3	-0.2
CF from investing activities	-9.3	-11.0
Purchase of investments in securities	-0.8	0.0
Purchase of PPE	-8.7	-11.0
Others	0.2	0.0
CF from financing activities	-5.1	-10.0
Dividends paid	-4.1	-4.0
Borrowings	-1.0	-1.0
Purchase of treasury shares	0.0	-5.0
Others	0.0	0.0
Effect of FX rate changes on cash & cash equivalents	-0.1	0.0
Change in cash & cash equivalents	6.8	1.4
Cash & cash equivalents at end of period	27.9	29.3

(Blank)

FY2012 Sales Outlook by Segment

(¥billion)

		FY2011		FY20112E			Change		
	1H	2H	Total	1HE	1HE 2HE Total			2H E	Total
Chem	18.6	18.3	36.9	18.4	20.1	38.5	-0.2	1.8	1.6
Fine Chemicals	5.9	5.0	10.9	5.7	6.1	11.8	-0.2	1.1	0.9
Basic Chemicals	12.7	13.3	26.0	12.7	14.0	26.7	0.0	0.7	0.7
Performance Materials	17.0	17.0	34.0	17.5	19.7	37.2	0.5	2.7	3.2
Agro	12.5	21.3	33.8	13.0	21.6	34.6	0.5	0.3	0.8
Pharma	5.2	4.8	10.0	4.9	4.1	9.0	-0.3	-0.7	-1.0
Trading	22.5	22.3	44.8	22.3	24.9	47.2	-0.2	2.6	2.4
Others	9.3	10.7	20.0	9.2	13.5	22.7	-0.1	2.8	2.7
Adjustment	-15.3	-15.6	-30.9	-15.9	-20.3	-36.2	-0.6	-4.7	-5.3
Total	69.8	78.8	148.6	69.4	83.6	153.0	-0.4	4.8	4.4

FY2012 OP Outlook by Segment

(¥billion)

	ı	FY2011		F	Y20112	E	(Change	;	
	1H	2H	Total	1HE	1HE 2HE Total			1HE 2HE Total		
Chem	8.0	8.0	1.6	0.6	1.7	2.3	-0.2	0.9	0.7	
Fine Chemicals	-	-	-	-	-	-	-	-	-	
Basic Chemicals	-	•	•	-	•	-	•	•	-	
Performance Materials	2.6	2.2	4.8	2.7	3.6	6.3	0.1	1.4	1.5	
Agro	8.0	3.6	4.4	8.0	3.4	4.2	0.0	-0.2	-0.2	
Pharma	2.6	2.0	4.6	2.3	1.7	4.0	-0.3	-0.3	-0.6	
Trading	0.7	0.6	1.3	0.6	8.0	1.4	-0.1	0.2	0.1	
Others	0.0	0.3	0.3	0.1	0.3	0.4	0.1	0.0	0.1	
Adjustment	-0.9	-0.6	-1.5	-0.8	-0.6	-1.4	0.1	0.0	0.1	
Total	6.6	8.9	15.5	6.3	10.9	17.2	-0.3	2.0	1.7	

FY2012 YOY Outlook by Segment

(Chemicals)

(Basic Chemicals) ◆OP up

- ◆Market conditions expected to be weak in 1H
- ◆Sales of urea/AdBlue and high purity sulfuric acid up in 2H
- Slight recovery in melamine expected in 2H
- Fixed cost down

(Fine Chemicals) ◆OP up

- ◆Market conditions expected to be weak in 1H
- ◆Sales of Custom Chemicals up in 2H, demand for TEPIC up in 2H
- Fixed cost down

(Total Segment) Sales up ¥1.6billion, OP up ¥0.7billion

(Performance Materials)

- ◆Sales up ¥3.2billion. OP up ¥1.5billion
- ◆ Recovery in demand for SUNEVER, Inorganic Materials expected
- ◆Sales of new products up 79%
- **♦**Recovery of BARC and Inorganic Materials expected in 2H

(Agro)

- ♦ Sales down ¥0.8billion, OP down ¥0.2billion
- ♦In-house developed products sales up (STARMITE, LEIMAY, NC-620 in Korea, etc.)
- ◆Milestones on the animal health products expected
- ◆Depreciation cost up (new Biological Research Laboratories), R&D expenses up

(Pharmaceuticals)

- ◆Sales down ¥1.0billion (LIVALO down ¥0.1billion, milestones down ¥0.4billion, others down ¥0.5billion), OP down ¥0.6billion
- **♦LIVALO** volume up, but National Health Insurance drug price cut 8%

(Trading)

- ◆Sales up ¥2.4billion, OP up ¥0.1billion
- Recovery in trading activities expected in 2H


Chemicals – ① Fine Chemicals subsegment

			Non	-cons	olidat	ed Sa	les YC	Y Cha	nge	
Product	Characteristics and Trend		FY2011 Outlook as of Oct. 2011			FY2011 Actual			Y2012	E
		1H Actual	2H E	FY 2011E	1H Actual	2H Actual	FY 2011	1H E	2H E	FY 2012E
Total Subsegment		-3%	+13%	+4%	-3%	-3%	-3%	-4%	+21%	+8%
TEPIC	 ◆ Epoxy compound for: solder resist, LED sealant, powder coating hardening agent for paintt (automobiles, electric appliances) ◆ World largest producer (FY2011) Sales down due to strong yen and weak electronics market (FY2012) Demand expected to recover in 2H Focusing on development of new liquid TEPIC 	-12%	+4%	-4%	-12%	-13%	-12%	-2%	+18%	+8%
Environmental related products	♦ HI-LITE: made from chlorinated isocyanuric acid, used for sterilizing, disinfectant for swimming pool as well as water purification tank (FY2011) Sales down due to the Earthquake as well as strong yen (FY2012) Demand expected to recover in 2H	-11%	+6%	-4%	-11%	-14%	-12%	-5%	+22%	+6%
Custom Chemicals	◆ Custom manufacturing and process researching services for pharma companies ◆ New plant completed in Onoda in July 2010 (capex ¥ 2.0 billion) (FY2011) Sales up due to new contracts (FY2012) Sales up Increase in work on existing contracts New contracts expected Decrease in depreciation cost	+29%	+23%	+27%	+29%	+39%	+33%	-12%	+40%	+11%

Four products account for 80% of total non-consolidated subsegment sales (FY2011)

Chemicals – ② Flow Chart of Selected Basic and Fine Chemicals Products

- ◆ Core products of Basic Chemicals : Ammonia related products and sulfuric acid related products
- **♦** FY2011 ammonia domestic market share 8%, large percentage of self-consumption of ammonia



(agent used for cleaning semiconductors)

Chemicals – ② Basic Chemicals subsegment

			Non	-cons	olidat	ed Sa	les YC	Y Cha	nge	
Product	Characteristics and Trend	FY2011 Outlook as of Oct. 2011			FY2011 Actual			FY2012E		
		1H Actual	2H E	FY 2011E	1H Actual	2H Actual	FY 2011	1H E	2H E	FY 2012E
Total Subsegment		+2%	+4%	+3%	+2%	-8%	-3%	+0%	+6%	+3%
Melamine	 ◆ Mainly used as adhesive agent for particle board, medium density fiberboard, plywood (FY2011) Sales for both domestic and export market sluggish due to the Earthquake, strong yen and weak Asian market (FY2012) Sales down 1% vs. FY2011 Weak demand expected to continue in 1H, slight recovery expected in 2H 	-4%	-13%	-13%	-12%	-37%	-26%	-10%	+8%	-1%
Urea including AdBlue	 ◆ Urea: mainly used for urea formaldehyde resin, adhesive agent ◆ AdBlue: solution of urea in demineralised water for diesel trucks to reduce NOx (FY2011) Sales up due to strong marketing efforts, supported by new domestic NOx rules on diesel trucks (FY2012) Sales up based on continued marketing efforts 	+16%	+52%	+35%	+16%	+28%	+22%	+36%	+26%	+31%
High purity sulfuric acid	 ◆ Used to clean semiconductors ◆ Largest domestic producer ◆ Capacity expansion(+15%) completed in May 2011 to accommodate increase in demand (FY2011) Sales up slightly due to weak semiconductors market (FY2012) Weak demand expected toncontinue in 1H, but sales up in 2H in line with semiconductors recovery 	-1%	+21%	+10%	-1%	+2%	+1%	-1%	+13%	+6%

Performance Materials – (1) SUNEVER

2H FY2011 Actual

(vs. 2H FY2010)

Sales down 7%

Remarkable IPS/FFS (for tablet PC and smart phone) sales increase, but large sales decrease

in TN and VA due to customers' production cut

(vs. 2H FY2011 Outlook as of October 2011)

Sales down vs. October 2011 outlook

VA above expectations, but TN and IPS/FFS below expectations because of smaller customers' volume

◆FY2012 YOY Outlook Sales up 14%

Recovery in panel market

Sales increase in IPS/FFS and VA

♦ Development of various new alignment technologies progressing

◆Technical Service Center in Taiwan completed in April 2011

				Consolidated Sales YOY Change									
	Major Use	Jse School Street Stree			FY2011 Actual			FY2012E					
		1H Actual	2H E	FY 2011E	1H Actual	2H Actual	FY 2011	1H E	2H E	FY 2012E			
Total SUNEVER		-23%	+4%	-10%	-23%	-7%	-15%	+10%	+18%	+14%			
TN (twisted nematic)	PC, monitor	-31%	-16%	-25%	-31%	-25%	-28%	-16%	-4%	-10%			
IPS/FFS (in plane switching / fringe field switching)	TV, tablet PC,	-13%	+26%	+6%	-13%	+13%	+0%	+36%	+34%	+35%			
VA (vertical alignment)	smart phone	1070	12070	1070	1070	1 10 70	1070	10070	10470	100 /0			

Electronic Materials – ② BARC (bottom anti-reflective coating for semiconductor)

◆ 2H FY2011 Actual (vs. 2H FY2010)

Sales down due to sluggish demand for KrF and non-BARC ArF (BARC ArF volume up)

(vs. 2H FY2011 Outlook as of October 2011)

Sales down due to weak demand for KrF and ArF

◆FY2012 YOY Outlook Sales down 4%

Continued weak semiconductors market in 1H, recovery expected in 2H (BARC ArF volume up)

			Consolidated Sales YOY					Change				
	Line Width	as of		FY2011		as of I			F	Y2012E		
		1H Actual	2H E	FY 2011E	1H Actual	2H Actual	FY 2011	1H E	2H E	FY 2012E		
Total BARC		-15%	-1%	-8%	-15%	-9%	-12%	-5%	-2%	-4%		
KrF	130nm~110nm	-19%	-7%	-13%	-19%	-16%	-18%	-12%	-5%	-9%		
ArF(1)	90nm>	-12%	+2%	-5%	-12%	-5%	-9%	-2%	+0%	-1%		

(1) Including Non-BARC application

Performance Materials – 3 Inorganic Materials

4 New Products

Inorganic Materials (SNOWTEX, Organo sol)

	Product Characteristics and Trend		Non-consolidated Sales YOY Change									
Product			FY2011 Outlook as of October 2011			FY2011 Actual			FY2012E			
		1H Actual	2H E	FY 2011E	1H Actual	2H Actual	FY 2011	1H E	2H E	FY 2012E		
	 ♦ Silica sol for : polishing silicon wafer/aluminum and glass hard disk, NOx reduction catalyst, automobile catalyst, chrome-free electrical steel sheet ♦ Largest domestic producer, major global producer ♦ New second plant in Toyama completed in March 2011 (production capacity +20%) (2H FY2011) Sluggish demand for polishing applications as well as non-polishing applications (FY2012) In 2H, recovery of demand for all applications expected 		+17%	+4%	-9%	-24%	-16%	-10%	+29%	+7%		
	◆ Used for hard coating materials, electronic information materials ◆ World largest producer (2H FY2011) Demand for certain electronic information up (FY2012) In 2H, recovery of demand for electronic information materials expected	-5%	+42%	+16%	-5%	+12%	+2%	-1%	+28%	+13%		

New Products

Sales of new products such as multi layer process materials, 3DTV materials, NHC (protection layer of touch panel) increasing substantially Sales YOY change: FY2011 Actual +36%, FY2012 Outlook +79%

(Blank)

Agrochemicals – ①

- **♦**Stable profit center
- Strengthening product portfolio by: (a) in-house developed products, (b) acquired products, (c) licensed-in products
 - (a) In-house developed products: LEIMEY(fungicide), STARMITE(miticide) in FY2008
 - (b) Acquired products : ROUNDUP(herbicide, acquired from Monsanto) in FY2002,

THIFLUZAMIDE(fungicide, acquired from Dow) in FY2009

(c) Licensed-in products : PREVATHON(insecticide, licensed from DuPont) in FY2009,

AVH(herbicide, licensed from ZEN-NOH, Bayer and Hokko) in FY2010

♦Pipeline

(a) In-house developed products: NC620 (paddy rice herbicide, launch FY2013)

Animal health product (licensing product, launch FY2014)

(c) Licensed-in products : Fruits/vegetables/paddy rice insecticide, Fruits/vegetables/tea insecticide,

Fruits/vegetables fugicide

- **♦** Full reconstruction of Biological Research Laboratories (FY2010-2015)
- ◆Acquired 3% share of IHARABRÁS (leading agro company in Brazil) in September 2011 to strengthen R&D and marketing capabilities in the rapidly growing market in Latin America
- Main products:

ROUNDUP(herbicide), SIRIUS(herbicide), PERMIT(herbicide), TARGA(herbicide), THIFLUZAMIDE(fungicide), STARMITE(insecticide), LEIMEY(fungicide), BUTACHLOR(herbicide), SANMITE(insecticide)

- ⇒9 products account for 66% of total non-consolidated segment sales before discount(FY2011)
- **♦** Export sales account for about 20% of total non-consolidated segment sales(FY2011) (Asia:49%, Europe,Africa:24%, North/Central/South America:27%)


Agrochemicals – ② Non-consolidated Segment Sales (before discount)


	Non-	Non-consolidated Sales YOY Change (before discou						
	FY2011 Outlook as of October 2011					FY2012E		
	1H	2H E	FY	1H	2H	FY	1 120122	
	Actual	211 =	2011E	Actual	Actual	2011		
ROUNDUP	+33%	+0%	+9%	+33%	+0%	+9%	+0%	
Except ROUNDUP	-2%	+1%	+0%	-2%	-4%	-3%	+4%	
Total Segment	+4%	+0%	+2%	+4%	-3%	-1%	+3%	

	Distributi	on of NCI				
	Non-consolidated Sales					
	FY2010	FY2011				
Fungicide +Insecticide	3%	2%				
Insecticide	19%	18%				
Fungicide	11%	13%				
Herbicide	62%	65%				
Plant growth regulator	2%	2%				
Others	2%	1%				

Pharmaceuticals – (1) NCI Business Model

- Steadily expanding segment in mid-term perspective
- Unique ethical pharma business model without sales force





Pharmaceuticals – ③ LIVALO World Wide Strategy

Country /Region	Stage of Development	Launch (schedule)	Business partner
Japan	Launched	Sep 2003	Kowa, Daiichi-Sankyo
Korea	Launched	Jul 2005	JW Pharmaceutical
Thailand	Launched	Jan 2008	Biopharm-Chemical
China	Launched	Jul 2009	Kowa Shanghai
USA	Launched	Jun 2010	Kowa(KPA), Eli Lilly
Europe	Launched	May 2011	Kowa(KPE), Recordati
Mexico	Launched	Feb 2012	Eli Lilly
Indonesia	Launched	May 2012	Indonesia Tanabe
Taiwan	Approved	2012	Taiwan Tanabe
Australia	Approved	2012	Abbott

Pharmaceuticals – 4 Pipeline

Product	Market		Developing Status	Licensee	Expected Market Size (¥ billion)
NM/NT-702 (Anti-platelet agent)	Japan	Intermittent claudication	- Phase II	Taisho	20-30
		Asthma			20
	EU/USA	Intermittent claudication	Phase II completed	Indigo(USA)	50-70(USA)
NTC-801 (Anti-arrhythmic agent)	Japan		Phase II	Teijin	1 million patients(2015)
	World wide(except Japan)		Phase II	BMS	8.4 million patients(2015)
NIP-022 (Platelet generating stimulator agent)			Phase I	Ono	0.35million patients (2015 in Japan)

Capex/Depreciation/R&D by Segment (¥ billion)

	Capex(1)					Depreciation(2)				R&D expenses						
(New Segment)	2008	2009	2010	2011	2012E	2008	2009	2010	2011	2012E	2008	2009	2010	2011	2012E	% of Sales
Chem	-	-	1.9	1.6	1.1	-	-	3.4	2.5	2.2	-	-	0.8	0.8	0.7	1.8%
Perf. Materials	-	-	3.7	2.2	3.2	-	-	4.1	4.3	4.0	-	-	5.6	6.2	6.6	17.7%
Agro	-	-	0.4	2.1	3.0	-	-	1.9	1.8	2.0	-	-	2.6	2.8	3.0	8.7%
Pharma	-	-	2.4	1.7	0.6	-	-	0.3	1.0	1.2	-	-	2.4	2.5	2.5	27.8%
Trading	-	-	0.2	0.1	0.1	-	-	0.1	0.1	0.1	-	-	0.0	0.0	0.0	0.0%
Others	-	-	1.0	0.6	0.6	-	-	0.6	0.8	0.5	-	-	1.2	1.3	1.4	6.2%
Total	13.9	10.1	9.6	8.3	8.6	10.2	11.0	10.4	10.5	10.0	13.7	13.1	12.6	13.6	14.2	
	R&D expenses/Sales (%) 8.6% 8.8% 8.2% 9.2% 9.3%															

(1) Capex

Actual - Acceptance basis

Outlook - Production commencement basis

(2) Depreciation Method

SUNEVER, BARC- 4 year declining balance method (50.0% of initial capex amount in the 1st year)

Other products - 8 year declining balance method (25.0% of initial capex amount in the 1st year)

Number of R&D Personnel (Sept.2011) - ①	420 (Parent company)
Number of Professionals (Sept.2011) - ②	1,035 (Parent company)
①/②	41%

FY2012 Main Capex Items (Approval basis)

2012E						
項目	金額					
High purity ammonia	0.4					
SUNEVER(NCK)	0.4					
BARC(NCK)	0.9					
Electronic Materials Labo (Building)	2.9					
Electronic Materials Labo (Instruments)	1.1					
Biological Research Labo	0.9					

Financial Strategy – ① Purchase of Treasury Shares

- Started purchase of treasury shares in 2006 to enhance ROE
- ◆ Purchased ¥20.5 billion, 16.4 million shares (8.8% of shares issued) in total
- Cancelled purchased shares

Record of purchase of treasury shares FY2006 - 11

年度	FY2006	FY2007	FY2008	FY2009	FY2010	FY2011	FY2006- FY2011 Total
Shares purchased (thousand shares)	3,500	3,399	7,355	0	2,167	0	16,421
Purchase costs (¥ billion)	4.7	5.0	8.0	0	2.8	0	20.5
Shares cancelled (thousand shares)	3,000	3,635	7,000	0	3,000	0	16,635
Shares issued at FY end (thousand shares)	184,635	181,000	174,000	174,000	171,000	171,000	
Treasury stock at FY end (thousand shares)	1,367	1,233	1,660	1,709	885	886	
Dividend (¥ billion)	3.7	3.6	3.8	4.2	4.1	4.1	23.5
Dividend (¥ / Share)	20	20	22	24	24	24	
Total payout ratio (dividend + purchase of treasury shares) (%)	61	56	117	32	53	37	58

♦ Notification on May 15, 2012

(1) Total number of shares to be purchased: Up to 7 million shares

(2) Total amount of purchase costs of share: Up to ¥ 5 billion

(3) Purchase period : From May 16, 2012 to October 31, 2012

Financial Strategy – 2 Cash Management Policy


- Aiming to control cash balance around the level of:

```
Minimum required level

+
1/3 of annual scheduled long-term borrowings repayment
+
1/3 of short-term borrowings outstanding
+
Contingent risk reserves (added for FY2011)

(non-consolidated basis)
```

Long-term Financial Performance Trend



(1) 2002 = From April 1, 2002 to March 31, 2003

Long Term Financial Performance Trend

	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
Sales	151.9	155.9	161.4	169.1	174.4	169.2	160.2	149.0	154.2	148.6
Operating Profit	9.8	15.7	17.3	21.7	20.8	24.8	17.4	19.2	19.8	15.5
Ordinary Income	8.6	14.6	17.4	21.3	21.2	24.4	16.9	19.2	19.4	15.9
Net Income	4.0	8.7	11.3	13.7	14.0	15.5	10.1	12.8	13.0	11.0
EBITDA	20.7	26.1	26.9	31.6	30.5	34.5	27.6	30.1	30.2	25.9
OP Margin	6.5%	10.0%	10.7%	12.8%	12.0%	14.6%	10.9%	12.8%	12.9%	10.4%
ROE(%)	6.7%	13.4%	15.2%	16.1%	14.7%	15.6%	10.3%	12.6%	11.9%	9.5%
EPS(¥)	21.16	46.21	59.77	72.73	75.43	85.15	57.26	74.00	75.94	64.52
Dividend(¥/share)	9	11	11	15	20	20	22	24	24	24
Purches of treasury shares	-	-	-	-	4.7	5.0	8.0	-	2.8	-
Net Assets	60.6	69.2	78.5	92.0	98.1	100.1	95.7	106.5	112.4	119.6
Liabilities with interest	68.5	57.4	44.6	41.5	32.4	34.4	45.5	42.1	39.9	38.9
Equity ratio	35.4%	40.1%	46.4%	50.2%	55.3%	58.0%	55.5%	58.7%	60.7%	62.4%
Capex	18.8	6.6	6.6	9.2	12.1	10.9	13.9	10.1	9.6	8.3
Depreciation	10.9	10.4	9.6	9.9	9.7	9.7	10.2	11.0	10.4	10.5
R&D Expenses	7.5	8.7	8.6	9.2	9.9	12.5	13.7	13.1	12.6	13.6
R&D Expenses/Sales(%)	4.9%	5.6%	5.3%	5.4%	5.7%	7.4%	8.6%	8.8%	8.2%	9.2%
Number of employees (parent company)	1,514	1,505	1,502	1,502	1,558	1,614	1,657	1,710	1,750	1,730

Sales and Operating Profit by New Segmentation

		FY2	010	FY2	011	FY2012E		
	Chemicals	38.1	24.7%	36.9	24.8%	38.5	25.2%	
	Performance Materials	38.0	24.6%	34.0	22.9%	37.2	24.3%	
(0	Agrochemicals	34.4	22.3%	33.8	22.7%	34.6	22.6%	
SALE	Pharm acueticals	9.6	6.2%	10.0	6.7%	9.0	5.9%	
μ̈́	Trading	44.1	28.6%	44.8	30.1%	47.2	30.8%	
S	Others	27.0	17.5%	20.0	13.5%	22.7	14.8%	
	Adjustment	-37.0	-24.0%	-30.9	-20.8%	-36.2	-23.7%	
	Total	154.2	100%	148.6	100%	153.0	100%	
					•			
	Chemicals	2.4	12.1%	1.6	10.3%	2.3	13.4%	
	Performance Materials	7.9	39.9%	4.8	31.0%	6.3	36.6%	
	Agrochemicals	4.8	24.2%	4.4	28.4%	4.2	24.4%	
유	Pharm acueticals	4.4	22.2%	4.6	29.7%	4.0	23.3%	
D	Trading	1.4	7.1%	1.3	8.4%	1.4	8.1%	
	Others	1.0	5.1%	0.3	1.9%	0.4	2.3%	
	Adjustment	-2.1	-10.6%	-1.5	-9.7%	-1.4	-8.1%	
	合計	19.8	100%	15.5	100%	17.2	100%	
					•			
	Chemicals		6.3%		4.3%		6.0%	
0	Performance Materials		20.8%		14.1%		16.9%	
P	Agrochemicals		14.0%		13.0%		12.1%	
OP Margin	Pharmacueticals		45.8%		46.0%		44.4%	
rgi	Trading		3.2%		2.9%		3.0%	
ח	Others		3.7%		1.5%		1.8%	
	合計		12.9%		10.4%		11.2%	

Pro Forma Sales and Operating Profit by Former Segmentation(1)

		FY2	005	FY2	006	FY2	007	FY2008		FY2009		FY2010	
	Chemicals	50.2	29.7%	55.2	31.6%	60.7	35.9%	55.4	34.6%	46.1	30.9%	49.6	32.2%
	Electronic Materials	23.4	13.9%	22.8	13.1%	28.1	16.6%	23.2	14.5%	26.6	17.9%	26.2	17.0%
ဟ	Agrochemicals	35.8	21.1%	33.5	19.2%	33.2	19.6%	35.4	22.1%	33.8	22.7%	34.4	22.3%
ĕ	Pharm aceuticals	5.1	3.0%	6.5	3.7%	8.1	4.8%	9.2	5.7%	9.5	6.4%	9.6	6.2%
ļμ	Trading	35.7	21.1%	40.4	23.2%	47.0	27.8%	46.3	28.9%	41.3	27.7%	44.1	28.6%
ဟ	Others (2)	53.4	31.6%	53.4	30.6%	28.0	16.5%	28.4	17.7%	27.4	18.4%	27.0	17.5%
	Adjustment	-34.4	-20.3%	-37.4	-21.4%	-35.9	-21.2%	-37.7	-23.5%	-35.7	-24.0%	-36.7	-23.8%
	Total	169.2	100%	174.4	100%	169.2	100%	160.2	100%	149.0	100%	154.2	100%
	Chemicals	4.6	21.3%	5.4	25.8%	6.3	25.4%	3.6	20.7%	2.6	13.5%	4.1	20.7%
	Electronic Materials	11.1	51.3%	9.4	45.0%	10.3	41.5%	4.9	28.2%	7.3	38.0%	6.2	31.3%
	Agrochemicals	3.7	17.2%	3.5	16.7%	4.1	16.5%	5.0	28.7%	4.7	24.5%	4.8	24.2%
유	Pharm aceuticals	1.2	5.6%	2.1	10.0%	3.9	15.7%	4.5	25.9%	4.6	24.0%	4.4	22.2%
ס	Trading	0.8	3.8%	1.0	4.6%	1.0	4.0%	1.1	6.3%	1.1	5.7%	1.4	7.1%
	Others	0.9	4.1%	1.1	5.4%	0.8	3.2%	0.7	4.0%	1.0	5.2%	1.0	5.1%
	Adjustment	-0.7	-3.3%	-1.6	-7.4%	-1.6	-6.3%	-2.4	-13.8%	-2.1	-10.9%	-2.1	-10.6%
	Total	21.7	100%	20.8	100%	24.8	100%	17.4	100%	19.2	100%	19.8	100%
	Chemicals		9.2%		9.8%		10.3%		6.5%		5.6%		8.3%
0	Electronic Materials		47.4%		41.1%		36.8%		21.0%		27.4%		23.7%
ס	Agrochemicals		10.4%		10.4%		12.3%		14.0%		13.9%		14.0%
Ma	Pharm aceuticals Pharm aceuticals		24.0%		32.2%		48.0%		49.5%		48.4%		45.8%
Margin	Trading		2.3%		2.4%		2.2%		2.4%		2.7%		3.2%
ם	Others		1.7%		2.1%		2.7%		2.5%		3.6%		3.7%
	Total		12.8%		11.9%		14.6%		10.9%		12.8%		12.9%

- (1) FY2005-2008 are restated based on new segmentation
- (2) Sales of Others decreased in FY2007 mainly due to spin-off of Nissan Agri (currently "Sun Agro") (fertilizer company, actual FY2006 sales ¥27.7 billion)

FY2010- 11 Quarterly Sales by Segment

(New Segmentation)(1)

			FY2010			FY2011						
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total		
Chem	9.6	8.9	9.8	9.8	38.1	9.4	9.2	9.0	9.3	36.9		
Fine Chemicals	3.3	2.8	2.5	2.7	11.3	3.0	2.9	2.4	2.6	10.9		
Basic Chemicals	6.3	6.1	7.3	7.1	26.8	6.4	6.3	6.6	6.7	26.0		
Performance Materials	10.4	9.3	9.0	9.3	38.0	8.7	8.3	8.6	8.4	34.0		
Agro	6.9	5.1	4.4	18.0	34.4	7.1	5.4	3.7	17.6	33.8		
Pharma	2.5	2.3	2.1	2.7	9.6	2.9	2.3	2.4	2.4	10.0		
Trading	10.7	10.5	11.8	11.1	44.1	11.6	10.9	10.8	11.5	44.8		
Others	6.5	4.6	4.3	11.6	27.0	4.6	4.7	4.3	6.4	20.0		
Adjustment	-7.6	-7.6	-8.7	-13.1	-37.0	-7.7	-7.6	-7.3	-8.3	-30.9		
Total	39.0	33.1	32.7	49.4	154.2	36.6	33.2	31.5	47.3	148.6		

⁽¹⁾ FY2010 are restated based on new segmentation

FY2010- 11 Quarterly OP by Segment

(New Segmentation)(1)

		ı	FY2010			FY2011					
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	
Chem	1.1	-0.5	0.9	0.9	2.4	1.0	-0.2	0.6	0.2	1.6	
Performance Materials	2.6	2.3	1.6	1.4	7.9	1.7	0.9	1.1	1.1	4.8	
Agro	8.0	0.0	-1.4	5.4	4.8	1.2	-0.4	-1.5	5.1	4.4	
Pharma	1.2	0.9	1.1	1.2	4.4	1.4	1.2	1.0	1.0	4.6	
Trading	0.4	0.3	0.4	0.3	1.4	0.4	0.3	0.3	0.3	1.3	
Others	0.1	0.0	-0.1	1.0	1.0	0.0	0.0	-0.1	0.4	0.3	
Adjustment	-0.4	-0.5	-0.3	-0.9	-2.1	-0.5	-0.4	-0.4	-0.2	-1.5	
Total	5.8	2.5	2.2	9.3	19.8	5.2	1.4	1.0	7.9	15.5	

⁽¹⁾ FY2010 are restated based on new segmentation

FY2009- 10 Quarterly Sales by Segment

(Former Segmentation)

			FY2009)		FY2010					
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	
Chem	11.3	10.8	12.0	12.0	46.1	12.7	11.8	12.4	12.7	49.6	
Organic/Inorganic Materials	4.5	4.5	5.0	5.2	19.2	5.4	5.0	4.8	5.1	20.3	
Basic Chemicals	6.8	6.3	7.0	6.8	26.9	7.3	6.8	7.6	7.6	29.3	
Electronic Materials	6.4	6.8	6.8	6.6	26.6	7.3	6.4	6.3	6.2	26.2	
Agro	8.0	3.7	3.7	18.4	33.8	6.9	5.1	4.4	18.0	34.4	
Pharma	2.2	2.8	2.9	1.6	9.5	2.5	2.3	2.1	2.7	9.6	
Trading	10.3	9.8	10.4	10.8	41.3	10.7	10.5	11.8	11.1	44.1	
Others	8.2	5.1	7.0	7.1	27.4	6.5	4.6	4.3	11.6	27.0	
Adjustment	-11.1	-7.5	-9.1	-8.0	-35.7	-7.6	-7.6	-8.6	-12.9	-36.7	
Total	35.3	31.5	33.7	48.5	149.0	39.0	33.1	32.7	49.4	154.2	

FY2009- 10 Quarterly OP by Segment

(Former Segmentation)

	FY2009						FY2010				
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	
Chem	1.2	-0.7	1.0	1.1	2.6	1.6	0.2	1.1	1.2	4.1	
Electronic Materials	2.1	2.6	1.3	1.3	7.3	2.1	1.7	1.4	1.0	6.2	
Agro	1.0	-0.7	-1.3	5.7	4.7	8.0	0.0	-1.3	5.3	4.8	
Pharma	1.2	1.5	1.5	0.4	4.6	1.2	0.9	1.0	1.3	4.4	
Trading	0.2	0.3	0.3	0.3	1.1	0.4	0.3	0.4	0.3	1.4	
Others	0.5	-0.1	0.2	0.4	1.0	0.1	0.0	-0.1	1.0	1.0	
Adjustment	-0.9	-0.4	-0.6	-0.2	-2.1	-0.4	-0.6	-0.3	-0.8	-2.1	
Total	5.3	2.5	2.4	9.0	19.2	5.8	2.5	2.2	9.3	19.8	

Main Products by Segment (New Segmentation)

Segment	Products	Main Applications					
Chem	♦Fine Chemicals						
	TEPIC	epoxy compound for LED sealants, solder resist, painting					
	Melamine cyanurate	flame retardant					
	Environmetal product	HI-LITE (chlorinated isocyanuric acid for sterilizing)					
	Custom Chemicals	custom manufacturing and process services for pharmaceutical companies					
	♦ Basic Chemicals						
	Melamine	adhesive agent for plywood					
	AdBlue	solution of urea in demineralised water for diesel trucks to reduce NOx					
	Ammonia, Sulfuric acid, Nitric acid						
	Highpurity chemicals	agents used for cleaning semiconductors					
Performance	◆ Electronic Materials						
Materials	SUNEVER	LCD alignment coating					
	BARC	bottom anti-reflective coating for semiconductors					
	NHC	protective coating for touch panel					
	Micro lens	microlens material for image sensor application					
	♦ Inorganic Materials						
	SNOWTEX	water dispersed colloidal sillica sol for polishing sillicon wafers, electrical steel					
		sheets, NOx reduction catalyst, electronic printing materials					
	Organo sillica sol	film coating, antistatic interference shielding, electronic printing materials					
	Alumina sol	automotive catalyst, electronic printing materials					
	SUNCOLLOID	high refractive sol for lens					
	CELNAX	antistatic sol for film					
Agro	♦ Herbicides						
	TARGA	soybean, rapeseed, sugarbeet					
	PERMIT	corn, sugarcane, rice					
	SIRIUS	rice					
	ROUNDUP	non-selective herbicide for orchard, noncrop land					
	♦ Insecticides						
		fruits,tea, vegetables					
	♦ Fungicide						
	LEIMAY, IKARUGA	potato, grape, turf					
Pharma	LIVALO	Anti-cholesterol drug					
Trading	Nissei Corporation						
Others	Transportation, Landscaping, Engineering, Fertilizer						

Main Products by Segment (Former Segmentation)

Segment	Products	Main Applications
Chem	◆ Organic Materials	
	TEPIC	epoxy compound for LED sealants, solder resist, painting
	Custom Chemicals	custom manufacturing and process services for pharmaceutical companies
	Melamine cyanurate	flame retardant
	◆Inorganic Materials	
	SNOWTEX	water dispersed colloidal sillica sol for polishing sillicon wafers, electrical steel sheets, NOx reduction catalyst, electronic printing materials
	Organo sillica sol	film coating, antistatic interference shielding, electronic printing materials
	Alumina sol	automotive catalyst, electronic printing materials
	SUNCOLLOID	high refractive sol for lens
	CELNAX	antistatic sol for film
	♦ Basic Chemicals	
	Melamine	adhesive agent for plywood
	AdBlue	solution of urea in demineralised water for diesel trucks to reduce NOx
	Environmetal product	HI-LITE (chlorinated isocyanuric acid for sterilizing)
	Ammonia, Sulfuric acid, Nitric acid	
	Highpurity chemicals	agents used for cleaning semiconductors
Electronic	SUNEVER	LCD alignment coating
Materials	BARC	bottom anti-reflective coating for semiconductors
	NHC	protective coating for touch panel
	Micro lens	microlens material for image sensor application
Agro	♦ Herbicides	
	TARGA	soybean, rapeseed, sugarbeet
	PERMIT	corn, sugarcane, rice
	SIRIUS	rice
	ROUNDUP	non-selective herbicide for orchard, noncrop land
	◆Insecticides	
	STARMITE, SANMITE, MITOKOHNE	fruits,tea, vegetables
	◆ Fungicide	
	LEIMAY, IKARUGA	potato, grape, turf
Pharma	LIVALO	Anti-cholesterol drug
Trading	Nissei Corporation	
Others	Transportation, Landscaping, Engineering, Fertilizer	

Forward Looking Statements

The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncertainties. Actual results may largely differ from these statements due to various factors which may be beyond company control.

No information in this material is provided as an offer to buy or sell the shares of the company. We urge users of the material to make investment decision based upon own judgment.